Partnering to Enable Solutions for Allogeneic Cell Therapy Industrialization

Joining Forces To Foster Advances In Allogeneic Cell Therapy Industrialization

Allogeneic cell therapies represent a new modality that will allow more patients to be treated using healthy donor-derived cells. However, even as the field begins to show success in clinical trials and beyond, critical bottlenecks related to chemistry, manufacturing, and controls (CMC) pose challenges for bringing these therapies to patients on a global scale. From a joint vision and combining complementary strengths, Bayer and Cytiva have teamed up to develop and deliver solutions for producing allogeneic cell therapies at the scale and quality required by the industry.

WHAT TO EXPECT

• Presentation: Bayer and Cytiva focus on the scientific, technical, and cultural transformations required to drive toward true industrialization of allogeneic cell therapies, including:
• Reviewing the background foundation of the allogeneic cell therapies landscape
• Identifying the critical CMC challenges of producing cell therapies
• Understanding why partnering is essential to deliver industry enabling technological innovations
• Learning how equipment and automation enhancements drive efficient manufacturing
• Implementing our collaborative approach to create flexible platform solutions for industrialization